Arcturus Therapeutics Holdings Inc. Common Stock (ARCT)

Price$7.30

Value ScoreB

Growth ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-0.41%

Price vs S&P 500 (4W)-20.81%

VGM Score56.49

Market Capitalization$207.49M

All Metrics

Book Value / Share (Quarterly)$6.73

P/TBV (Annual)2.36x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-26.43%

Cash Flow / Share (Quarterly)$-2.06

Price vs S&P 500 (YTD)10.93%

Net Profit Margin (TTM)-143.80%

EPS (TTM)$-2.82

10-Day Avg Trading Volume0.42M

EPS Excl Extra (TTM)$-2.82

Revenue Growth (5Y)53.90%

EPS (Annual)$-2.40

ROI (Annual)-30.74%

Net Profit Margin (5Y Avg)-357.81%

Cash / Share (Quarterly)$7.44

Revenue Growth QoQ (YoY)-92.99%

ROA (Last FY)-24.26%

Revenue Growth TTM (YoY)-61.92%

EBITD / Share (TTM)$-3.08

ROE (5Y Avg)-32.16%

Operating Margin (TTM)-161.52%

Cash Flow / Share (Annual)$-2.62

P/B Ratio1.08x

P/B Ratio (Quarterly)1.15x

Net Income / Employee (Annual)$-620,600

EV / Revenue (TTM)-0.07x

Net Interest Coverage (TTM)8.07x

ROA (TTM)-28.40%

EV / EBITDA (TTM)-0.04x

EPS Incl Extra (Annual)$-2.40

Current Ratio (Annual)6.64x

Quick Ratio (Quarterly)6.19x

3-Month Avg Trading Volume0.46M

52-Week Price Return-38.71%

EV / Free Cash Flow (Annual)97.69x

Revenue / Employee (TTM)$516,100

Tangible BV / Share (Quarterly)$10.48

P/S Ratio (Annual)2.53x

Asset Turnover (Annual)0.30x

52-Week High$24.17

Operating Margin (5Y Avg)-362.44%

EPS Excl Extra (Annual)$-2.40

CapEx CAGR (5Y)-33.28%

Tangible BV CAGR (5Y)51.57%

26-Week Price Return7.51%

Quick Ratio (Annual)6.50x

13-Week Price Return0.69%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.31x

Enterprise Value$-3.89M

Revenue / Share Growth (5Y)44.96%

Asset Turnover (TTM)0.20x

Book Value / Share Growth (5Y)-13.03%

Revenue / Employee (Annual)$773,900

Pretax Margin (Annual)-80.19%

Cash / Share (Annual)$8.13

3-Month Return Std Dev62.23%

Net Income / Employee (TTM)$-742,200

ROE (Last FY)-30.74%

Net Interest Coverage (Annual)19.72x

EPS Basic Excl Extra (Annual)$-2.40

P/FCF (TTM)1.00x

Receivables Turnover (TTM)6.88x

EV / Free Cash Flow (TTM)3.61x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.82

Receivables Turnover (Annual)17.20x

ROI (TTM)-36.55%

P/S Ratio (TTM)3.79x

Pretax Margin (5Y Avg)-357.47%

Revenue / Share (Annual)$3.00

Tangible BV / Share (Annual)$10.18

Price vs S&P 500 (52W)-63.07%

Year-to-Date Return19.09%

5-Day Price Return-6.05%

EPS Normalized (Annual)$-2.40

ROA (5Y Avg)-20.90%

Net Profit Margin (Annual)-80.19%

Month-to-Date Return-7.83%

Cash Flow / Share (TTM)$3.73

EBITD / Share (Annual)$-2.67

Operating Margin (Annual)-92.96%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-28.42%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-2.82

P/TBV (Quarterly)2.28x

P/B Ratio (Annual)0.81x

Pretax Margin (TTM)-143.80%

Book Value / Share (Annual)$7.53

Price vs S&P 500 (13W)-7.57%

Beta2.37x

P/FCF (Annual)8.55x

Revenue / Share (TTM)$1.92

ROE (TTM)-36.55%

52-Week Low$5.85

vGradeB

gGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.95est. -1.11

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.06

4.05

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ARCTArcturus Therapeutics Holdings Inc. Common Stock	B	D	C	$7.30
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Arcturus Therapeutics develops mRNA medicines focused on infectious disease vaccines and rare liver and respiratory disease therapies. Its pipeline includes vaccine candidates for influenza and COVID-19 variants, as well as programs for rare genetic conditions. The company aims to address significant unmet medical needs in high-value therapeutic areas.